drugset / Trial / NCT00075504

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

NCT00075504

Phase 2 Completed 33 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well giving 3-AP together with gemcitabine works in treating patients with unresectable or metastatic bile duct or gallbladder cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may help gemcitabine kill more cancer cells by making them more sensitive to the drug.

Timeline

Start
2003-11
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Triapine Small molecule 80 mg/m2 Intravenous
Subject Triapine Small molecule 105 mg/m2 Intravenous

Indications